Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares fell 4.1% on Tuesday . The company traded as low as $39.50 and last traded at $39.98, with a volume of 204,333 shares trading hands. The stock had previously closed at $41.71.

A number of brokerages recently weighed in on AGIO. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Sunday, March 27th. Canaccord Genuity raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $50.00 to $90.00 in a research note on Monday, June 13th. Janney Montgomery Scott reaffirmed a “neutral” rating and issued a $47.00 price target (down from $52.00) on shares of Agios Pharmaceuticals in a research note on Monday, June 13th. SunTrust Banks Inc. raised their price target on shares of Agios Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, May 18th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, May 24th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $69.67.

The stock has a 50 day moving average price of $48.34 and a 200 day moving average price of $45.83. The stock’s market capitalization is $1.52 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.18. The company had revenue of $31.30 million for the quarter, compared to analyst estimates of $20.94 million. The company’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) earnings per share. Analysts forecast that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $65.00, for a total value of $1,787,500.00. Following the sale, the insider now owns 81,376 shares of the company’s stock, valued at $5,289,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 627 shares of the company’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $40.37, for a total transaction of $25,311.99. Following the completion of the sale, the director now directly owns 125,921 shares in the company, valued at approximately $5,083,430.77. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in AGIO. Mutual of America Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 86 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 1,624 shares during the period. Rhumbline Advisers increased its stake in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock valued at $1,620,000 after buying an additional 605 shares during the period. ProShare Advisors LLC increased its stake in shares of Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock valued at $2,029,000 after buying an additional 1,740 shares during the period. Finally, GAM Holding AG increased its stake in shares of Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 31,000 shares during the period.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.